The US Food and Drug Administration has issued a warning letter to CanaRx Services of Detroit, Michigan, which supplies the Massachusetts city of Springfield with prescription drugs from Canada under a unique voluntary program offered to enrollees in its employee and retiree health plans (Marketletter August 18).
In its letter, the agency tells the firm it considers its operations to be illegal and a risk to public health. CanaRx runs an Internet web site and mail operation that illegally cause the shipment of prescription drugs from a Canadian pharmacy in the USA, "subjecting Americans to risky imported drug products and making misleading assurances to consumers about the safety of its drugs," says the FDA.
"Firms like this should not continue to profit through illegal actions that put the health of the American public at risk," said FDA Commissioner Mark McClellan. "Our investigation has shown that CanaRx operates a drug purchasing arrangement that channels drugs through companies other than licensed pharmacies and does not consistently use shipping practices that ensure its drugs are safe and effective."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze